Stability Indicating Isocratic HPLC Method for Bilastine and Characterization of Forced Degradation Products by LC-MS/MS
Pharmaceutical Science-Pharmaceutics
DOI:
https://doi.org/10.22376/ijlpr.2023.13.SP1.P83-P93Keywords:
Bilastine, Stability Indicating HPLC Method, Degradation Products, LC-MS/MS, CharacterizationAbstract
Abstract: The present study aims to develop and validate a simple, precise, accurate, stability indicating and isocratic reversephase high-performance liquid chromatography (RP-HPLC) method for estimating Bilastine in bulk and synthetic mixture. Bilastine from its degradation products were well separated and estimated on Discovery C8 column (250 mm x 4.6 mm, 5μm) using methanol: 0.1% ortho-phosphoric acid (55:45 %v/v) as a mobile phase and detection was performed at 276 nm by PDA detector. The degradation of Bilastine was studied under different ICH recommended stress conditions. The developed stability-indicating method was validated for system suitability, linearity, accuracy, precision, robustness, detection limit and quantitation as per ICH guidelines. The method was linear over 25-150 μg/ml. Mathematically computed Limit of Detection and Limit of Quantitation were found to be 0.19μg/ml and 0.57μg/ml, respectively. It was discovered that Bilastine degrades under acid and oxidation conditions. By using LC-MS/MS analysis, the structure of Bilastine breakdown products created amid acidic and oxidative settings was elucidated. A complete fragmentation pathway of Bilastine was established to elucidate the degradation products' structures using LC–MS/MS. The elemental concentrations of oxidation products and their fragmentation products were studied using the acquired mass values. The overall data was utilized to describe the degradation of products and their fragmentation process. The developed method can be used for routine analysis of Bilastine in dosage form as it can estimate of Bilastine in presence of excipients and degradation products.
References
Ridolo E, Montagni M, Bonzano L, Incorvaia C, Canonica GW. Bilastine: new insight into antihistamine treatment. Clin Mol Allergy. 2015;13(1):1. doi: 10.1186/s12948-015-0008-x, PMID 25878559.
Scaglione F. Safety profile of bilastine: 2nd generation H1-antihistamines. Eur Rev Med Pharmacol Sci. 2012;16(14):1999-2005. PMID 23242729.
ICH. Stability testing of new drug substances and products, international Conference on Harmonization, Geneva, February, 2003. Vol. Q1A. (p. R2).
WHO. Stability testing of active pharmaceutical ingredients and pharmaceutical products. Geneva: World Health Organization; 2007.
Bakshi M, Singh S. Development of validated stability-indicating assay methods–critical review. J Pharm Biomed Anal. 2002;28(6):1011-40. doi: 10.1016/s0731-7085(02)00047-x, PMID 12049968.
Jelena T, Igor P, Ana S, Anja T, Biljana J. J Pharm Biomed Anal. 2016;125:385-93.
Andressa TDS, Gabriela RB, Isadora DM, Lisiane B, Marcelo DM, Clésio SP. Drug anal res. 2017;1:38-43.
2016. Bilastine detection method, CN104730194B.
Lucero ML, Arteche JK, Sommer EW, Casadesus A. Preclinical toxicity profile of oral bilastine. Drug Chem Toxicol. 2012;35(sup1):25-33. doi: 10.3109/01480545.2012.682652.
Togawa M, Yamaya H, Rodríguez M, Nagashima H. Pharmacokinetics, Pharmacodynamics and Population Pharmacokinetic/Pharmacodynamic Modelling of Bilastine, a Second-Generation Antihistamine, in Healthy Japanese Subjects. Clin Drug Investig. 2016;36(12):1011-21. doi: 10.1007/s40261-016-0447-2, PMID 27498100.
Berrueta LA, Fernández-Armentia M, Bakkali A, Gonzalo A, Lucero ML, Orjales A. Matrix solid-phase dispersion technique for the determination of a new antiallergic drug, bilastine, in rat faeces. J Chromatogr B. 2001;760(1):185-90. doi: 10.1016/S0378-4347(01)00267-5.
Lasseter KC, Sologuren A, La Noce AL, Dilzer SC. Evaluation of the single-dose pharmacokinetics of bilastine in subjects with various degrees of renal insufficiency. Clin Drug Investig. 2013;33(9):665-73. doi: 10.1007/s40261-013-0110-0, PMID 23873362.
Lucero ML, Gonzalo A, Ganza A, Leal N, Soengas I, Ioja E et al.. Interactions of bilastine, a new oral H 1 antihistamine, with human transporter systems. Drug Chem Toxicol. 2012;35(sup1):8-17. doi: 10.3109/01480545.2012.682653.
Ouarezki R, Guermouche S, Guermouche MH. Degradation kinetics of Bilastine determined by RP-HPLC method and identification of its degradation product in oxidative condition. Chem Pap. 2020;74(4):1133-42. doi: 10.1007/s11696-019-00956-x.
Motta PR, Dos Santos Porto D, Martini PRR, Bajerski L, Azeredo JB, Paula FR et al.. Bilastine: Quantitative Determination by LC with Fluorescence Detection and Structural Elucidation of the Degradation Products Using HRMS. J AOAC Int. 2020;103(6):1451-60. doi: 10.1093/jaoacint/qsaa059, PMID 33247742.
US Cent Drug Eval Res Reviewer Guid Validation Chromatogr Methods. November 1994.
Green JM. Peer Reviewed: a Practical Guide to Analytical Method Validation. Anal Chem. 1996;68(9):305A-9A. doi: 10.1021/ac961912f.
General Chapter. Validation of compendial methods Convention. Inc. 2007. United States Pharmacopeia. Rockville, MD: The United States Pharmacopeial; 1225. p. 30, National Formulary 25.
Cope AC, Foster TT, Towle PH. Thermal Decomposition of Amine Oxides to Olefins and Dialkylhydroxylamines. J Am Chem Soc. 1949;71(12):3929-34. doi: 10.1021/ja01180a014.
Kalariya PD, Talluri MVNK, Patel PN, Srinivas J. Pharm biome anal. 2015;102:353-65. doi: 10.1016.
Hartauer KJ, Arbuthnot GN, Baertschi SW, Johnson RA, Luke WD, Pearson NG et al.. Influence of peroxide impurities in povidone and crospovidone on the stability of raloxifene hydrochloride in tablets: identification and control of an oxidative degradation product. Pharm Dev Technol. 2000;5(3):303-10. doi: 10.1081/PDT-100100545, PMID 10934729.
Skibiński R, Trawiński J, Komsta Ł, Bajda K. Characterization of forced degradation products of clozapine by LC-DAD/ESI-Q-TOF. J Pharm Biomed Anal. 2016;131:272-80. doi: 10.1016/j.jpba.2016.09.007, PMID 27611099.
Vaghela B, Rao SS, Reddy AM, Venkatesh P, Kumar N. Identification and Characterization of an Oxidative Degradation Product of Fexofenadine, Development and Validation of a Stability-Indicating RP-UPLC Method for the Estimation of Process Related Impurities and Degradation Products of Fexofenadine in Pharmaceutical Formulations. Sci Pharm. 2012;80(2):295-309. doi: 10.3797/scipharm.1111-07, PMID 22896817.
Yang Y, Zhu X, Zhang F, Li W, Wu Y, Ding L. Stability-indicating HPLC method development and structural elucidation of novel degradation products in posaconazole injection by LC-TOF/MS, LC-MS/MS and NMR. J Pharm Biomed Anal. 2016;125:165-77. doi: 10.1016/j.jpba.2016.03.034, PMID 27023129.
Published
How to Cite
Issue
Section
Copyright (c) 2022 Dr. Shital Patel, Dr. T. Yunus Pasha
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
